I-Mab to Release Q3 2024 Financial Results on November 14, 2024

2024-11-01 I-Mab Biopharma HaiPress

ROCKVILLE,Md.,Oct. 31,2024 -- I-Mab (NASDAQ: IMAB) (the "Company"),a US-based,global biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer,today announced that it plans to release financial results for the third quarter ended September 30,2024,on Thursday,November 14,pre-market Eastern Time.

The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline,corporate strategy,and objectives. Information about financial results,conference calls,webcasts,and other information is posted on the Company's website.

AboutI-Mab

I-Mab (NASDAQ: IMAB) is a US-based,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.

I-Mab has established operations in Rockville,Maryland,and Short Hills,New Jersey.For more information,please visithttps://www.i-mabbiopharma.comand followus onLinkedInandX.

I-Mab Investor & Media Contacts

Tyler Ehler

Senior Director,Investor Relations

IR@imabbio.com

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

Newest